Skip to content

Which AML patients get lasting benefit from olutasidenib?
Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL
Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials
Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma
Data support COVID-19 vaccination in patients receiving CAR-T therapy

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Elias Jabbour, MD

Cellular Therapy

Elias Jabbour, MD

Leukemia

Elias Jabbour, MD

Lymphoma

Elias Jabbour, MD

Multiple Myeloma

Elias Jabbour, MD

Myelodysplastic Syndromes

Elias Jabbour, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

June 9, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Elias Jabbour, MD

Elias Jabbour, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
600 Views
2 years ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

Doctor at laptop

ASCO 2026, Acute Myeloid Leukemia, News

Which AML patients get lasting benefit from olutasidenib?

June 9, 2026

Dr. Marc Hoffman

ASCO 2026, Lymphoma, Aggressive B-Cell Lymphomas, Meetings / Conferences, News

Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL

June 9, 2026

Microscope in AI virtual pattern

ASCO 2026, Cellular Therapy, Multiple Myeloma, News

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

June 8, 2026

ASCO 2026, Trending now, Multiple Myeloma, SOHO Insider Podcast

Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma

June 5, 2026

ASCO 2026, Cellular Therapy, News

Data support COVID-19 vaccination in patients receiving CAR-T therapy

June 4, 2026

ASCO 2026, Trending now, Meetings / Conferences, Multiple Myeloma, News

Dr. Hans Lee on MRNA-2808 in relapsed or refractory multiple myeloma

June 4, 2026

Top Categories

Cellular Therapy

74

Leukemia

113

Lymphoma

128

Multiple Myeloma

97

Myelodysplastic Syndromes

39

Myeloproliferative Neoplasms

22

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Elias Jabbour, MD

Cellular Therapy

Elias Jabbour, MD

Leukemia

Elias Jabbour, MD

Lymphoma

Elias Jabbour, MD

Multiple Myeloma

Elias Jabbour, MD

Myelodysplastic Syndromes

Elias Jabbour, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Doctor at laptop

Which AML patients get lasting benefit from olutasidenib?

Dr. Marc Hoffman

Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL

Microscope in AI virtual pattern

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.